News - Oncology, Perjeta


Current filters:


Popular Filters

Greater brand-drug adoption fuels Asia-Pacific breast cancer market


Due to an increasing uptake of branded drugs in Asia-Pacific (APAC), the region’s breast cancer therapeutics…

afatinibAsia-PacificBoehringer IngelheimEisaiHalavenKadcylaMarkets & MarketingneratinibOncologypalbociclibPerjetaPfizerPharmaceuticalResearchRoche

Factors driving oncologists’ prescribing decisions for HER2-positive breast cancer patients

Factors driving oncologists’ prescribing decisions for HER2-positive breast cancer patients


Efficacy, more than any other factors, drives oncologists’ prescribing of targeted therapies for breast…

AfinitorbuparlisibGlaxoSmithKlineHerceptinMarkets & MarketingNovartisOncologyPerjetaPharmaceuticalRocheTykerb

Chugai launches Perjeta for breast cancer in Japan


Japanese drugmaker Chugai Pharmaceutical (TYO: 4519) has launched the anti-cancer agent Perjeta (pertuzumab)…

Asia-PacificChugai PharmaceuticalMarkets & MarketingOncologyPerjetaPharmaceutical

FDA advisory panel backs new indication for Genentech's Perjeta


The US Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) yesterday (September…

BiotechnologyGenentechKadcylaNorth AmericaOncologyPerjetaPharmaceuticalRegulationRoche

UK NICE guidance says breast cancer drug Perjeta not value for money


The UK's National Health Service (NHS) is to be advised that it should not routinely provide Swiss drug…


US FDA backs news indications for Latuda; grants Priority Review for Perjeta


Sunovion Pharmaceuticals, a US subsidiary of Japan's Dainippon Sumitomo Pharma (TYO: 4506), says that…

BiotechnologyDainippon Sumitomo PharmaLatudaNeurologicalNorth AmericaOncologyPerjetaPharmaceuticalRegulationRocheSunovion

Chugai gains Japanese approval for Perjeta and Bonviva


Japanese drugmaker Chugai Pharmaceutical (TYO: 4519) said this morning (June 28) that it has obtained…

Anti-Arthritics/RheumaticsAsia-PacificBonvivaChugai PharmaceuticalOncologyPerjetaPharmaceuticalRegulationRoche

Roche granted EU approval for Perjeta; board appointments


The European Medicines Agency has approved Swiss drug major Roche's (ROG: SIX) Perjeta (pertuzumab) for…


Growing patient population to drive Mexican breast cancer market


An expanding patient population will largely contribute to the growth of the market for treating breast…

AfinitorEisaiHalavenKadcylaMarkets & MarketingNovartisOncologyPerjetaPharmaceuticalRocheSouth Americatrastuzumab emtansine

San Antonio breast cancer meeting highlights


There was mixed news coming out of the San Antonio Breast Cancer Symposium (SABCS), which concluded on…


US oncologists' perceptions of Roche's Perjeta very promising


Swiss drug major Roche (ROG: SIX) and subsidiary Genentech's Perjeta (pertuzumab), which has been available…

afatinibAfinitorBiotechnologyGenentechMarkets & MarketingNorth AmericaOncologyPerjetaPharmaceuticalRoche

New entrants from Roche and Novartis will drive breast cancer market


Through 2021, the uptake of three new market entrants, Roche (ROG: SIX)/Genentech's Perjeta (pertuzumab)…

AfinitorBiotechnologyMarkets & MarketingNovartisOncologyPerjetaPharmaceuticalRoche

FDA backs Roche's personalized breast cancer therapy Perjeta


The US Food and Drug Administration on Friday approved Swiss drug major Roche (ROG: SIX) subsidiary Genentech's…

BiotechnologyGenentechNorth AmericaOncologyPerjetapertuzumabPharmaceuticalRegulationRoche

Back to top